Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

In fact, the share price is now only right around ... The company is currently working on vaccines for RSV and the seasonal flu, as well as some rare diseases. However, right now, it is still ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

A study done after the respiratory syncytial virus shots were approved suggests ... In 2021, federal regulators revised the fact sheet for Johnson & Johnson’s Covid-19 shot to warn about a ...

Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the ...

Doctors said on Monday said they're noticing an increase in illnesses including flu, RSV, norovirus and pneumonia ... each winter and combined with the fact that flu season this year has also ...

Meta announced this week it was ending third-party fact-checking and moving towards community notes. Some experts fear it could lead to a rise in health misinformation.

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Meta -- the company that operates Facebook, Instagram, Threads and WhatsApp --announced on Tuesday it was ending third-party fact-checking ... including COVID and RSV -- to protect themselves ...

A study done after the respiratory syncytial virus shots were approved suggests that people given ... In 2021, federal regulators revised the fact sheet for Johnson & Johnson’s Covid-19 shot to warn ...